Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
KKR & Co. Inc., also known as Kohlberg Kravis Roberts & Co., agreed to buy a stake in Cotiviti to accelerate innovation and growth. The American investment firm is acquiring the asset from Veritas Capital Fund Management, L.L.C., a private equity company based in New York City.
KKR & Co. is set to invest $11 billion to acquire a stake in Cotiviti. This amount would be one of the most significant new PEF transactions. On Wednesday, Feb. 14, the company said that KKR and Veritas Capital will have equal shares in the health tech firm once the deal is completed.
Financing for the Deal
The acquisition will boost KKR's portfolio of healthcare analytics investments. According to Axios, the agreement will include $5 billion worth of loans that JPMorgan would manage.
This arrangement with a leading investment company is said to be a major win for the traditional banking sector, which has mostly been yielding buyout financing to private credit companies.
JPMorgan will help KKR with financing its Cotiviti acquisition through loans. In any case, the deal is expected to be completed within the second quarter of this year.
KKR and Veritas Capital's Plans
The Wall Street Journal reported that KKR and Veritas Capital's deal now ranks among the most extensive negotiations in recent times. This is because buyout firms have decelerated dealmaking after the Federal Reserve started marking up interest rates in 2022, making debt to fund acquisitions more expensive and challenging to secure.
Meanwhile, under the agreement, KKR and Veritas will also hand out considerable capital to help accelerate innovation while funding investments for growth. They may expand their business, introduce new product development, and work together on some tech-related opportunities.
"I am excited to continue our partnership with Veritas and welcome KKR as a new partner. Since initially partnering with Veritas in 2016, we have dramatically expanded our scale and enhanced our value proposition to our customers," Cotiviti's chairman, president, and chief executive officer, Emad Rizk, M.D., said in a press release. "I look forward to collaborating with both KKR and Veritas to leverage our highly differentiated solutions to improve the cost and quality within the healthcare system."
Photo by: Cotiviti Press Room
